Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Market Cap
The (ELYM) share price is expected to decrease by NAN% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered ELYM. Price targets range from $ at the low end to $ at the high end. The current analyst consensus for ELYM is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assigned ELYM 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ELYM. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of ELYM.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
Data Not Found! | ||||
In 2023, ELYM generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ELYM's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 02 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The company has changed its name to "Climb Bio," reflecting its new focus on developing treatments for immune-mediated diseases.
Why It Matters - The name change to "Climb Bio" signals a strategic shift, potentially attracting investment due to a focused direction in developing treatments for immune-mediated diseases.
Thu, 03 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Climb Bio, Inc. (Nasdaq: CLYM) will host a virtual investor day on October 15, 2024, to update on its strategy for developing therapeutics for immune-mediated diseases.
Why It Matters - Climb Bio's virtual investor day signals potential strategic updates and insights into its immune-mediated disease therapeutics, which could influence stock performance and investor sentiment.
Wed, 11 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Eliem Therapeutics, Inc. (Nasdaq: ELYM) will participate in the Stifel 2024 Virtual Immunology and Inflammation Summit on September 17-18, 2024.
Why It Matters - Eliem Therapeutics' participation in the Stifel summit may signal potential insights into its pipeline, impacting investor sentiment and stock performance in the immunology sector.
Mon, 26 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Brett Kaplan, M.D. has been appointed as Chief Operating Officer, succeeding Nishi Rampal, M.D.
Why It Matters - Leadership changes can impact company strategy and operations, influencing investor confidence and potential stock performance.
Wed, 14 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Eliem Therapeutics completed its acquisition of Tenet Medicines and raised $120 million. The company has $220 million in cash to fund operations through 2027 and plans an Investor Day later this year.
Why It Matters - Eliem's acquisition of Tenet and $120 million funding enhance its financial stability, positioning it for growth in immunology, especially with key milestones for budoprutug ahead.
Fri, 28 Jun 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Eliem Therapeutics, Inc. (Nasdaq: ELYM) has been added to the Russell 2000® and Russell 3000® Indexes, effective June 28, 2024, following the annual reconstitution.
Why It Matters - Inclusion in the Russell 2000 and 3000 indexes can boost Eliem Therapeutics' visibility and attract institutional investment, potentially driving up stock demand and price.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
